Advertisement


Riccardo Lencioni, MD, on Hepatocellular Carcinoma: Transarterial Chemoembolization, Durvalumab, and Bevacizumab

2024 ASCO GI Cancers Symposium

Advertisement

Riccardo Lencioni, MD, of the University of Pisa School of Medicine, discusses phase III results from the EMERALD-1 study of durvalumab plus bevacizumab plus TACE (transarterial chemoembolization) in patients with embolization-eligible unresectable hepatocellular carcinoma. Compared with TACE alone, this combination is the first immune checkpoint inhibitor–based regimen to improve progression-free survival and has the potential to set a new standard of care in this disease, according to Dr. Lencioni (Abstract LBA432).



Related Videos

Hepatobiliary Cancer

Milind M. Javle, MD, on Cholangiocarcinoma: New Data on Tinengotinib as Monotherapy

Milind M. Javle, MD, of The University of Texas MD Anderson Cancer Center, discusses phase II results on tinengotinib, a next-generation FGFR inhibitor that seems to overcome acquired resistance and shows efficacy in patients with cholangiocarcinoma with other FGFR alterations who are not eligible for FGFR2-targeted treatments. A phase III global study is currently enrolling to further evaluate the efficacy and safety of this agent vs physician’s choice in FGFR-altered, chemotherapy- and FGFR-inhibitor–refractory or relapsed disease.

Gastroesophageal Cancer

Ken Kato, MD, PhD, on Advanced Esophageal Cancer: Biomarker Analyses From CheckMate 648

Ken Kato, MD, PhD, of Japan’s National Cancer Center Hospital, discusses the first comprehensive findings on biomarkers from the CheckMate 648 study. These results further corroborate the clinical efficacy of nivolumab plus chemotherapy and nivolumab plus ipilimumab in the first-line treatment of advanced esophageal squamous cell carcinoma. According to Dr. Kato, the data suggest an overall survival benefit across multiple biomarker subgroups (Abstract 252).

Gastroesophageal Cancer
Gastrointestinal Cancer

Anant Ramaswamy, DM, on Advanced Gastric Cancers: New Findings on Adding Docetaxel to Doublet

Anant Ramaswamy, DM, of Tata Memorial Centre, discusses phase III results of a study that added docetaxel to a doublet regimen of fluorouracil or capecitabine and oxaliplatin, which did not improve overall survival in patients with advanced gastroesophageal junction and gastric cancers. Continuing chemotherapy beyond 6 months also did not appear to improve survival in this population (Abstract LBA248).

Colorectal Cancer

Van K. Morris, MD, on Colon Cancer: ctDNA as a Predictive Biomarker

Van K. Morris, MD, of The University of Texas MD Anderson Cancer Center, discusses phase II results on using circulating tumor DNA (ctDNA) as a predictive biomarker of adjuvant chemotherapy in patients with stage II colon cancer. During the trial, no improvement in ctDNA clearance was observed after 6 months of chemotherapy following resection of disease. Dr. Morris notes that future trials should account for evolving assay performance in patients with colorectal cancer (Abstract 5).

Gastrointestinal Cancer
Neuroendocrine Tumors

Lorraine A. Chantrill, PhD, MBBS, on Gastrointestinal Neuroendocrine Carcinomas: First-Line Treatment With Nab-Paclitaxel Plus Carboplatin

Lorraine A. Chantrill, PhD, MBBS, of Australia’s Wollongong Hospital, New South Wales, discusses phase II findings on the combination of nab-paclitaxel plus carboplatin as a first-line treatment for patients with gastrointestinal neuroendocrine carcinomas. According to Dr. Chantrill, this regimen appears to be active in these tumors and warrants further evaluation in a phase III trial (Abstract 589).

Advertisement

Advertisement




Advertisement